CDA and acute myeloid leukemia: CDA polymorphism (79A>C) is significantly correlated with shorter overall survival in comparison to wild-type CDA in AML patients [18], and a high CDA/DCK ratio is a risk factor for resistance to DAC in MDS patients [11].